316 related articles for article (PubMed ID: 23359006)
1. Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center.
Shirai Y; Yasuoka H; Takeuchi T; Satoh T; Kuwana M
Mod Rheumatol; 2013 Nov; 23(6):1211-20. PubMed ID: 23359006
[TBL] [Abstract][Full Text] [Related]
2. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.
Oudiz RJ; Schilz RJ; Barst RJ; Galié N; Rich S; Rubin LJ; Simonneau G;
Chest; 2004 Aug; 126(2):420-7. PubMed ID: 15302727
[TBL] [Abstract][Full Text] [Related]
3. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease.
Yasuoka H; Shirai Y; Tamura Y; Takeuchi T; Kuwana M
Circ J; 2018 Jan; 82(2):546-554. PubMed ID: 28904255
[TBL] [Abstract][Full Text] [Related]
5. Epoprostenol Therapy for Pulmonary Arterial Hypertension.
Akagi S; Nakamura K; Matsubara H; Ogawa A; Sarashina T; Ejiri K; Ito H
Acta Med Okayama; 2015; 69(3):129-36. PubMed ID: 26101188
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
[TBL] [Abstract][Full Text] [Related]
7. Rapid initiation of intravenous epoprostenol infusion is the favored option in patients with advanced pulmonary arterial hypertension.
Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Kuwana M; Fukuda K; Satoh T
PLoS One; 2015; 10(4):e0121894. PubMed ID: 25844932
[TBL] [Abstract][Full Text] [Related]
8. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
[TBL] [Abstract][Full Text] [Related]
9. Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
Rhee RL; Gabler NB; Praestgaard A; Merkel PA; Kawut SM
Arthritis Rheumatol; 2015 Sep; 67(9):2457-65. PubMed ID: 26016953
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III.
Stevenson MD; Macdonald FC; Langley J; Hunsche E; Akehurst R
Value Health; 2009; 12(8):1100-5. PubMed ID: 19558373
[TBL] [Abstract][Full Text] [Related]
11. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
[TBL] [Abstract][Full Text] [Related]
12. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol.
Badesch DB; McGoon MD; Barst RJ; Tapson VF; Rubin LJ; Wigley FM; Kral KM; Raphiou IH; Crater GD
J Rheumatol; 2009 Oct; 36(10):2244-9. PubMed ID: 19723905
[TBL] [Abstract][Full Text] [Related]
13. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
[TBL] [Abstract][Full Text] [Related]
14. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.
Badesch DB; Hill NS; Burgess G; Rubin LJ; Barst RJ; Galiè N; Simonneau G;
J Rheumatol; 2007 Dec; 34(12):2417-22. PubMed ID: 17985403
[TBL] [Abstract][Full Text] [Related]
15. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry.
Bergot E; Sitbon O; Cottin V; Prévot G; Canuet M; Bourdin A; de Groote P; Rottat L; Gressin V; Jaïs X; Humbert M; Simonneau G
Int J Cardiol; 2014 Apr; 172(3):561-7. PubMed ID: 24529947
[TBL] [Abstract][Full Text] [Related]
16. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment.
Fisher KA; Serlin DM; Wilson KC; Walter RE; Berman JS; Farber HW
Chest; 2006 Nov; 130(5):1481-8. PubMed ID: 17099027
[TBL] [Abstract][Full Text] [Related]
17. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival of patients with pulmonary arterial hypertension recovering to World Health Organization functional class I or II: a historical comparison between intravenous epoprostenol and oral agents.
Yamamoto K; Takeda Y; Takeda Y; Naniwa T; Narita H; Ohte N
BMC Res Notes; 2014 Jun; 7():359. PubMed ID: 24920465
[TBL] [Abstract][Full Text] [Related]
19. How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?
Barst R
Int J Clin Pract Suppl; 2010 Nov; (168):23-32. PubMed ID: 20939843
[TBL] [Abstract][Full Text] [Related]
20. Epoprostenol treatment in children with severe pulmonary hypertension.
Lammers AE; Hislop AA; Flynn Y; Haworth SG
Heart; 2007 Jun; 93(6):739-43. PubMed ID: 17065181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
